Bicara Therapeutics BCAX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's other accrued liabilities?
- Bicara Therapeutics (BCAX) reported other accrued liabilities of $238K in Q1 2026.
- How has Bicara Therapeutics's other accrued liabilities changed year-over-year?
- Bicara Therapeutics's other accrued liabilities increased by 290.2% year-over-year, from $61K to $238K.
- What is the long-term trend for Bicara Therapeutics's other accrued liabilities?
- Over 2 years (2023 to 2025), Bicara Therapeutics's other accrued liabilities has grown at a 40.3% compound annual growth rate (CAGR), from $92K to $181K.